Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AEON
stocks logo

AEON

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
--
--
-13.680
-86.95%
--
--
-0.350
-106.56%
--
--
-0.430
-96.27%
Estimates Revision
Stock Price
Go Down
down Image
-1.91%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Aeon Biopharma Inc (AEON.A) is 0.00, compared to its 5-year average forward P/E of -0.82. For a more detailed relative valuation and DCF analysis to assess Aeon Biopharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.82
Current PE
0.00
Overvalued PE
3.87
Undervalued PE
-5.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

AEON News & Events

Events Timeline

(ET)
2025-11-20
08:41:08
Aeon Biopharma Announces New Date for BPD Type 2a Meeting with FDA
select
2025-11-14 (ET)
2025-11-14
08:33:18
Aeon Biopharma Announces Q3 Earnings Per Share of 39 Cents Compared to a Loss of $11.24 Last Year
select
2025-10-01 (ET)
2025-10-01
08:17:45
Aeon Biopharma Reveals FDA Meeting Scheduled for ABP-450 Under BPD Type 2a Designation
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-24Newsfilter
AEON Biopharma Completes First PIPE Closing, Raising Approximately $1.79 Million
  • Funding Progress: AEON Biopharma completed its first PIPE closing on November 18, 2025, raising approximately $1.79 million. This funding will support the analytical program for its ABP-450 biosimilar, potentially accelerating development by up to six months.
  • FDA Meeting Reschedule: The FDA has rescheduled AEON's Biosimilar Biological Product Development Type 2a meeting to January 21, 2026, from the original date of November 19, 2025. This meeting will review AEON's analytical development plan and initial data, indicating continued FDA engagement with the program.
  • Market Opportunity: AEON aims to enter the U.S. therapeutic neurotoxin market, which exceeds $3 billion annually, with its ABP-450 product. The product has already been approved as a biosimilar in India, Mexico, and the Philippines, showcasing its international market potential.
  • Strategic Importance: The successful PIPE financing provides AEON with essential funding to ensure ongoing development and competitiveness in the biopharmaceutical sector. The CEO expressed anticipation for the FDA meeting to facilitate rapid entry into the U.S. market.
[object Object]
Preview
4.0
10-09Benzinga
Aegis Capital Affirms Buy Rating for AEON Biopharma, Keeps $7.2 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to enhance their market strategies and decision-making.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, catering to serious traders.

[object Object]
Preview
5.0
05-24Newsfilter
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

  • Stock Awards Announcement: AEON Biopharma has granted 102,880 restricted stock units (RSUs) to newly hired non-executive employees as part of its Inducement Incentive Plan, with a vesting schedule over four years starting from May 21, 2025.

  • Company Overview: AEON is focused on developing its botulinum toxin complex, ABP-450, for therapeutic uses, and holds exclusive rights for its distribution in several regions including the U.S. and Europe, while also having an experienced management team in biopharmaceutical development.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aeon Biopharma Inc (AEON) stock price today?

The current price of AEON is 0.7485 USD — it has decreased -8.1 % in the last trading day.

arrow icon

What is Aeon Biopharma Inc (AEON)'s business?

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.

arrow icon

What is the price predicton of AEON Stock?

Wall Street analysts forecast AEON stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AEON is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aeon Biopharma Inc (AEON)'s revenue for the last quarter?

Aeon Biopharma Inc revenue for the last quarter amounts to -2.53M USD, decreased -37.00 % YoY.

arrow icon

What is Aeon Biopharma Inc (AEON)'s earnings per share (EPS) for the last quarter?

Aeon Biopharma Inc. EPS for the last quarter amounts to -2596000.00 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Aeon Biopharma Inc (AEON)'s fundamentals?

The market is revising No Change the revenue expectations for AEON for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.91%.
arrow icon

How many employees does Aeon Biopharma Inc (AEON). have?

Aeon Biopharma Inc (AEON) has 5 emplpoyees as of December 05 2025.

arrow icon

What is Aeon Biopharma Inc (AEON) market cap?

Today AEON has the market capitalization of 8.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free